Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-18T02:29:26.895Z Has data issue: false hasContentIssue false
  • English
  • Français

Factors That Impact Choice of Antidepressant Treatment in Medically Complex Patients

Published online by Cambridge University Press:  07 November 2014

Pedro Luis Dago
Pedro Luis Dago*
Affiliation:
Dr. Dago is assistant professor of psychiatry in the Department of Psychiatry and Behavioral Sciences at, the Feinberg School of Medicine of Northwestern University in Chicago.
*
Pedro Luis Dago, MD, assistant professor of psychiatry, Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine of Northwestern University, 446 East Ontario Avenue, Chicago, IL 60611-3008; Tel: 312-695-2608; Fax: 312-695-5010; E-mail: PDago@nmff.org.
Get access Rights & Permissions [Opens in a new window]

Abstract

In medically complex patients with multiple comorbid illnesses who require concomitant medications, selecting the optimal antidepressant (ie, low risk of adverse effects and/or pharmacokinetic interactions) for an individual patient is critical for positive long-term patient outcomes. The serotonin-norepinephrine reuptake inhibitors (SNRIs) are increasingly being used as first-line treatment for major depressive disorder (MDD) and may prove beneficial for treatment of medically complex patients. Thus, it is key for clinicians to evaluate the differences in the pharmacokinetic and tolerability profiles of the SNRI class of antidepressants, evaluating differences both within the class and compared with other antidepressants used to treat MDD.

Type
Research Article
Information
CNS Spectrums , Volume 14 , Issue S12 , 2009 , pp. 20 - 27
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bymaster, FP, Dreshfield-Ahmad, LJ, Threlkeld, PG, et al.Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25(6):871–880.Google Scholar
2.Koch, S, Hemrick-Luecke, SK, Thompson, LKet al.Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology. 2003;45(7):935–944.Google Scholar
3.Deecher, DC, Beyer, CE, Johnston, G, et al.Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657–665.Google Scholar
4. Effexor [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2004.Google Scholar
5. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007.Google Scholar
6. Ixel [package insert]. France: Pierre Fabre Medicaments; 2003.Google Scholar
7. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2008.Google Scholar
8. Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2008.Google Scholar
9.Hiemke, C, Härtter, S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85(1):11–28.CrossRefGoogle ScholarPubMed
10.Spina, E, Santoro, V, D'Arrigo, C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clin Ther. 2008;30(7):1206–1227.Google Scholar
11.Otton, SV, Ball, SE, Cheung, SW, Inaba, T, Rudolph, RL, Sellers, EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996;41(2):149–156.Google Scholar
12.Skinner, MH, Kuan, HY, Pan, A, et al.Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73(3):170–177.Google Scholar
13.Puozzo, C, Leonard, BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol. 1996;11(suppl 4):15–27.Google Scholar
14.Alfinito, PD, Huselton, C, Chen, X, Deecher, DC. Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res. 2006;1098(1):71–78.Google Scholar
15.Ball, SE, Ahern, D, Scatina, J, Kao, J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol. 1997;43(6):619–626.Google Scholar
16.Ereshefsky, L, Dugan, D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety. 2000;12(suppl 1):30–44.Google Scholar
17.Laugesen, S, Enggaard, TP, Pedersen, RS, Sindrup, SH, Brøsen, K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther. 2005;77(4):312–323.Google Scholar
18.Nichols, AI, Fatato, P, Shenouda, M, et al.The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219–228.Google Scholar
19.Patroneva, A, Connolly, SM, Fatato, P, et al.An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484–2491.CrossRefGoogle ScholarPubMed
20.Preskorn, SH, Nichols, AI, Paul, J, Patroneva, AL, Helzner, EC, Guico-Pabia, CJ. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract. 2008;14(6):368–378.Google Scholar
21.Puozzo, C, Panconi, E, Deprez, D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol. 2002;17(suppl 1):S25–S35.Google Scholar
22.Puozzo, C, Lens, S, Reh, C, et al.Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet. 2005;44(9):977–988.Google Scholar
23.Nelson, JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997;58(suppl 6):26–31.Google Scholar
24.Ferguson, JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22–27.Google Scholar
25.Stahl, SM, Grady, MM, Moret, C, Briley, M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732–747.Google Scholar
26.Hu, XH, Bull, SA, Hunkeler, EM, et al.Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959–965.Google Scholar
27.Rudolph, RL, Derivan, AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16(3 suppl 2):54S–59S.Google Scholar
28.Hudson, JI, Wohlreich, MM, Kajdasz, DK, Mallinckrodt, CH, Watkin, JG, Martynov, OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2005;20(5):327–341.Google Scholar
29.DeMartinis, NA, Yeung, PP, Entsuah, R, Manley, AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677–688.Google Scholar
30.Liebowitz, M, Manley, AL, Padmanabhan, SK, Ganguly, R, Tummala, R, Tourian, KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877–1890.Google Scholar
31.Rouillon, F, Warner, B, Pezous, N, Bisserbe, JC. Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group. Int Clin Psychopharmacol. 2000;15(3):133–40.Google Scholar
32.Clayton, AH, Pradko, JF, Croft, HA, et al.Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357–366.Google Scholar
33.Delgado, PL, Brannan, SK, Mallinckrodt, CH, et al.Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry. 2005;66(6):686–692.Google Scholar
34.Clayton, A, Kornstein, S, Prakash, A, Mallinckrodt, C, Wohlreich, M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007;4(4 pt. 1):917–929.Google Scholar
35.Clayton, AH, McGarvey, EL, Clavet, GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33(4):731–745.Google Scholar
36.Clayton, AH, McGarvey, EL, Clavet, GJ, Piazza, L. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull. 1997;33(4):747–753.Google Scholar
37.McGahuey, CA, Gelenberg, AJ, Laukes, CA, et al.The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25–40.Google Scholar
38.Clayton, AH, Kornstein, SG, Rosas, G, Guico-Pabia, C, Tourian, KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14(4):183–195.Google Scholar
39.Wise, TN, Perahia, DG, Pangallo, BA, Losin, WG, Wiltse, CG. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry. 2006;8(5):269–278.Google Scholar
40.Cunningham, LA, Borison, RL, Carman, JS, et al.A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14(2):99–106.CrossRefGoogle ScholarPubMed
41.Septien-Velez, L, Pitrosky, B, Padmanabhan, SK, Germain, J-M, Tourian, KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22(6):338–347.Google Scholar
42.Boyer, P, Montgomery, S, Lepola, U, et al.Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243–253.Google Scholar
43.Glassman, AH. Cardiovascular effects of antidepressant drugs: updated. J Clin Psychiatry. 1998;59(suppl 15):13–18.Google Scholar
44.Roose, SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J. 2000;140(suppl 4):84–88.Google Scholar
45.Thase, ME, Tran, PV, Wiltse, C, Pangallo, BA, Mallinckrodt, C, Detke, MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25(2):132–140.Google Scholar
46.Thase, ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59(10):502–508.Google Scholar
47.Liebowitz, M, Yeung, PP, Entsuah, R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68(11):1663–1672.Google Scholar
48.Joffe, P, Larsen, FS, Pedersen, V, Ring-Larsen, H, Aaes-Jorgensen, T, Sidhu, J. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol. 1998;54(3):237–242.Google Scholar
49.Areberg, J, Christophersen, JS, Poulsen, MN, Larsen, F, Molz, KH. The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J. 2006;8(1):E14–E19.CrossRefGoogle ScholarPubMed
50.Démolis, JL, Angebaud, P, Grangé, JD, Coates, P, Funck-Brentano, C, Jaillon, P. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol. 1996;42(3):394–397.Google Scholar
51.Krastev, Z, Terziivanov, D, Vlahov, V, et al.The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr Scand Suppl. 1989;350:91–92.Google Scholar
52.Dalhoff, K, Almdal, TP, Bjerrum, K, Keiding, S, Mengel, H, Lund, J. Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol. 1991;41(4):351–354.Google Scholar
53.Doyle, GD, Laher, M, Kelly, JG, Byrne, MM, Clarkson, A, Zussman, BD. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand Suppl. 1989;350:89–90.Google Scholar
54.Aronoff, GR, Bergstrom, RF, Pottratz, ST, Sloan, RS, Wolen, RL, Lemberger, L. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984;36(1):138–144.Google Scholar
55.Bergstrom, RF, Beasley, CM Jr, Levy, NB, Blumenfield, M, Lemberger, L. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. Int Clin Psychopharmacol. 1993;8(4):261–266.Google Scholar
56. van Harten, J, Duchier, J, Devissaguet, JP, van Bemmel, P, de Vries, MH, Raghoebar, M. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet. 1993;24(2):177–182.Google Scholar
57.Crone, CC, Gabriel, GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004;43(6):361–394.Google Scholar
58.Wellington, K, Perry, CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs. 2001;15(8):643–669.Google Scholar
59.Troy, SM, Schultz, RW, Parker, VD, Chiang, ST, Blum, RA. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther. 1994;56(1):14–21.Google Scholar
60.McIntyre, RS, Panjwani, ZD, Nguyen, HT, et al.The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol. 2008;4(3):281–285.Google Scholar
61.Rudolph, RL, Fabre, LF, Feighner, JP, Rickels, K, Entsuah, R, Derivan, AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998;59(3):116–122.CrossRefGoogle ScholarPubMed
62.Macher, JP, Sichel, JP, Serre, C, von Frenckell, R, Huck, JC, Demarez, JP. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology. 1989;22(2):77–82.Google Scholar
63.Fava, M, Mulroy, R, Alpert, J, Nierenberg, AA, Rosenbaum, JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154(12):1760–1762.Google Scholar
64.Perahia, DG, Kajdasz, DK, Desaiah, D, Haddad, PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord. 2005;89(1-3):207–212.Google Scholar
65.Vandel, P, Sechter, D, Weiller, E, et al.Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Hum Psychopharmacol. 2004;19(8):585–586.Google Scholar
66.Papakostas, GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69 (suppl E1):8–13.Google Scholar
67.Zimmerman, M, Posternak, M, Friedman, M, et al.Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry. 2004;161(7):1285–1289.Google Scholar